Investor Presentaiton

GPRC5D iber/mezi Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab Broadening leadership across malignant and benign Hematology - Reblozyl: • . Recent FDA approval in 1L MDS-associated anemia with a broad label 1L TD Myelofibrosis associated anemia Phase 3 ongoing Numerous assets to extend leadership in Multiple Myeloma: • . . Abecma is under regulatory review in the triple class exposed population; Phase 3 initiating in patients with sub- optimal response post-ASCT GPRC5D CAR T as a potential first-in-class CART with registrational program initiating next year iberdomide & mezigdomide registrational data expected in 2026 • alnuctamab initiating Phase 3 next year Strengthening breadth of leadership across leukemias, lymphomas, and benign hematology: Best-in-class Breyanzi expanding across the broadest array of B-cell malignancies • • Golcadomide moving into Phase 3 in 1L LBCL BET inhibitor (BMS-986158) as a potential new option for patients with Myelofibrosis Addressing hematologic diseases impacting 4M+1 patients Ill Bristol Myers Squibb™ 1. 2023 estimates from Decision Resource Group & BMS Internal Analysis across indications in the U.S. & EU5 Not for Product Promotional Use 92

View entire presentation